Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Prognostic value of basal phenotype in HER2-overexpressing breast cancer.

Annals of surgical oncology - 1 Mar 2012

Bagaria Sanjay P, Ray Partha S, Wang Jinhua, Kropcho Luisa, Chung Alice, Sim Myung-Shin, Shamonki Jaime M, Martino Silvana, Cui Xiaojiang, Giuliano Armando E

Abstract excerpt

BACKGROUND: Primary breast cancers that overexpress human epidermal growth factor receptor 2 have variable biological features and clinical outcomes. A subgroup of HER2-overexpressing tumors that express basal-like immunohistochemical markers-the so-called basal-HER2+ subtype--is associated with poor prognosis. We investigated the clinical relevance of this basal-HER2+ subtype within HER2-overexpressing breast...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Breast Neoplasms
Share to Immunohistochemistry

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Keratins

Share to Phenotype

Share to Prognosis

Share to Receptor, ErbB-2

Share to Receptors, Estrogen

Share to Survival Rate

Source

Identifiers

PMID: 21879270
DOI: 10.1245/s10434-011-2032-5

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Prognostic value of basal phenotype in HER2-overexpressing breast cancer.PMID 21879270Read ↗

Cytokeratin 5/6 fingerprinting in HER2-positive tumors identifies a poor prognosis and trastuzumab-resistant basal-HER2 subtype of breast cancer.Semantic proximity Read ↗

Basal phenotype breast cancer: implications for treatment and prognosis.Semantic proximity Read ↗

Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes.Semantic proximity Read ↗

EGFR associated expression profiles vary with breast tumor subtypeSemantic proximity Read ↗

Basal-like Breast Carcinoma: From Expression Profiling to Routine PracticeSemantic proximity Read ↗

Clinicopathological features and prognosis of HER2 low-expression breast cancer: a single-center retrospective studySemantic proximity Read ↗

Do HER2-Low Tumors Have a Distinct Clinicopathologic Phenotype?Semantic proximity Read ↗

Basal-HER2 phenotype shows poorer survival than basal-like phenotype in hormone receptor-negative invasive breast cancers.Semantic proximity Read ↗

Prognostic Value of HER2-Low Expression in Non-Metastatic Triple-Negative Breast Cancer and Correlation with Other BiomarkersSemantic proximity Read ↗

Basal-like breast carcinoma: a phenotypically distinct entity.Semantic proximity Read ↗

Basal breast cancer: a complex and deadly molecular subtype.Semantic proximity Read ↗

Identification of Subtypes in Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer Reveals a Gene Signature Prognostic of OutcomeSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.